RECURSION PHARMACEUTICALS, INC. (RXRX)

As of 14 August 2026, short interest in RXRX is 177,923,359 shares, down 2,837,182 shares over the last month. Over the last 48 readings it ranged from 56,030,343 shares (30 August 2024) to 184,440,829 shares (15 May 2026). The latest reading sits at the top of that range. At the reported average volume of 13.3M shares a day that is 13.4 days to cover, a crowded short.

<iframe src="https://xoomar.com/embed/stocks/rxrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of RXRX volume is 59.6%, up 1.0 points over the last five sessions. Over the last 52 readings it ranged from 28.8% (21 August 2026) to 68.0% (13 July 2026). The latest reading is 11.2 points above the 30-session average of 48.4%, on 4.2M shares reported.

As of 14 August 2026, the fails-to-deliver balance in RXRX is 37,071 shares, up 32,366 shares over the last settlement date. Over the last 52 readings it ranged from 6 shares (11 August 2026) to 3,037,759 shares (2 July 2026). The latest reading sits at the bottom of that range.

Insiders at RXRX reported 3 open-market sells worth $356K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Borgeson Blake on 2026-09-01.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

20 Form 144 notices on file for RXRX worth $5.0M at the prices reported; 20 in the last 90 days worth $5.0M. Latest: Borgeson Blake filed on 2026-09-01 to sell 30,000 shares ($100K) from 2026-09-01.

4 holders above 5% have filed on RXRX, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.5% of the class (44,541,605 shares), filed 2026-07-29 for an event on 2026-06-30.

7 of the 30 tracked managers held RXRX at their latest 13F, $181.9M in total at quarter-end prices. ARK Investment Management is the largest at $151.7M (1.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) RECURSION PHARMACEUTICALS, INC. reported revenue of $7.7M, down 60.1% from the same quarter a year earlier, and net loss of $131.0M (-0.25 diluted EPS). In FY 2025 it generated -$371.8M of operating cash flow.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.